- Inhibitors
- Antibodies
- Compound Libraries
- New Products
- Contact Us
Choose Your Country or Region
Australia
Austria
Belgium
Brazil
Canada
China
Czech Republic
Denmark
Finland
France
Germany
Greece
Hong Kong
Hungary
Iceland
India
Ireland
Israel
Italy
Japan
Korea
Luxembourg
Malaysia
Netherlands
New Zealand
Norway
Poland
Qatar
Romania
Saudi Arabia
Singapore
Spain
Sweden
Switzerland
Taiwan
Turkey
United Kingdom
United States
| Catalog No. | Product Name | Information | Selective / Pan | IC50 / Ki |
|---|---|---|---|---|
| S8859 | BMS-1166 | BMS-1166 is a novel and potent small molecule inhibitor of the PD-1/PD-L1 interaction with an IC50 of 1.4 nM. | Selective | PD-1/PD-L1 interaction, IC50: 1.4 nM |
| S8158 | PD-1/PD-L1 Inhibitor 3 | PD-1/PD-L1 Inhibitor 3(Programmed Death-1/Programmed Death-Ligand 1 Inhibitor 3)is a Macrocyclic inhibitor of PD-1/PD-L1 interaction with IC50 of 5.6 nM | Selective | PD-1/PD-L1 interaction, IC50: 5.6 nM |
| S7911 | BMS-1 | BMS-1 is a small-molecule inhibitor of PD-1/PD-L1 interaction with IC50 of 6 nM. | Selective | PD-1/PD-L1 interaction, IC50: 0.006 μM |
| S9863 | INCB086550 | INCB086550 (PD-1/PD-L1-IN-8) is a potent PD-1/PD-L1 inhibitor, with an IC50 <= 10 nM. | Selective | PD-1/PD-L1, IC50: <10 nM |
| S7912 | BMS202 | BMS202 is a small-molecule PD-1/PD-L1 interaction inhibitor with IC50 of 18 nM. | Selective | PD-1/PD-L1 interaction, IC50: 0.018 μM |
| S9610 | BMS-1001 | BMS-1001 is a potent inhibitor of PD-1/PD-L1 interaction with EC50 of 253 nM. BMS-1001 alleviates the inhibitory effect of the soluble PD-L1 on the T-cell receptor-mediated activation of T-lymphocytes. | Selective | PD-1/PD-L1, EC50: 253 nM |
There are no products matching the selection yet, if you have any question please do not hesitate to contact us.
Selleck
Tech Support
Tel: +1-832-582-8158 Fax: +1-832-582-8590
Email: sales@selleckchem.com
Tel: +49 221 3579 1301
Email:eu.quote@selleckchem.com
Products are for research use only. Not for human use. We do not sell to patients.
©Copyright 2013 Selleck Chemicals. All Rights Reserved.